Skip to main content
SpringerLink
Log in

Patented drugs small burden on total healthcare costs in Canada

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Canadian-Health-Policy-Institute. Public Drug Plans Are Rationing Access to New Drugs for Cost Reasons, but Study Shows That Spending on Innovative Medicines in Canada Is Affordable When Adjusted for Population, Inflation, GDP and Other Healthcare Costs: Canadian Health Policy Institute. Media Release : 26 Nov 2014. Available from: URL: http://www.canadianhealthpolicy.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patented drugs small burden on total healthcare costs in Canada. PharmacoEcon Outcomes News 717, 30 (2014). https://doi.org/10.1007/s40274-014-1755-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1755-5

Search

Navigation